# The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

> **NCT04664829** · PHASE1 · COMPLETED · sponsor: **National Cancer Centre, Singapore** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Bexarotene
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04664829
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2025-08-04
- **Final completion:** 2025-08-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04664829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04664829, "The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04664829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*